Arina I. Danilovich
Arina I. Danilovich has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Roman Sergeevich Tarasov
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний», Кемерово
15 shared publications - Vladimir I. Ganyukov
Research Institute for Complex Issues of Cardiovascular Diseases
7 shared publications - Ivan V. Ganyukov
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases
2 shared publications - Ирина Николаевна Сизова
Research Institute for Complex Issues of Cardiovascular Diseases
2 shared publications - Aleksey V. Evtushenko
Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Sciences
1 shared publication - Alina A. Khorlampenko
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 30 (2) , 67-76
Valve-in-valve methodologies in transcatheter atrioventricular re-replacement using balloon-expandable prostheses: a series of clinical cases
Introduction: Given the annual increase in the need for repeated heart valve replacement, which is a high-risk surgical procedure due to repeated surgical access against the background of severe adhesions, trauma and comorbidity of patients, the technique of transcatheter heart valve replacement is becoming increasingly relevant and preferable. Objective: To present in detail modern methodologies for transcatheter mitral and tricuspid valve replacement using clinical examples. Methods: The presented patients had dysfunction of a previously openly implanted mitral/tricuspid bioprosthesis according to clinical data and echocardiography. Taking into account the high risk of surgical intervention, resternotomy and comorbid condition, after analyzing multispiral computed tomography within the framework of the cardiac team (cardiologist, endovascular surgeon, cardiovascular surgeon) it was decided to perform endovascular transcatheter repeat replacement using the "valve-in-valve" method. In both cases, puncture vascular access through the common femoral vein was used. Results: Balloon-expandable heart valve prostheses were effectively implanted in patients in the atrioventricular positions, achieving satisfactory hemodynamic parameters. Local anesthesia and transthoracic echocardiography were used for transcatheter tricuspid valve replacement. Mitral valve replacement was performed under total intravenous anesthesia, artificial ventilation, using transesophageal echocardiography, ultra-frequent cardiac pacing, and puncture of the interatrial septum. No complications were detected in the intra- and postoperative periods. The patients were discharged on the seventh day after the intervention. Conclusion: The methodology of transcatheter atrioventricular heart valve replacement is presented using clinical cases as an example, the effectiveness and safety of endovascular mitral and tricuspid valve replacement using balloon-expandable prostheses are shown. Further studies are needed that can provide a comparative assessment of the technologies of transcatheter and surgical atrioventricular heart valve replacement based on the analysis of long-term surgical results. Received 29 April 2025. Revised 28 January 2026. Accepted 3 February 2026. Informed consent The patient's informed consent to use the records for medical purposes is obtained. Funding The study was carried out with financial support from the Ministry of Science and Higher Education of the Russian Federation as part of the research project "Endovascular and extracorporeal technologies for the prevention and treatment of structural heart pathology and critical conditions in cardiac surgery" (No. 0419-2026-0004). Conflict of interest The authors declare no conflict of interest. Contribution of the authors Conception and study design: R.S. Tarasov, V.I. Ganyukov Data collection and analysis: I.V. Ganyukov, A.I. Danilovich Statistical analysis: I.V. Ganyukov, A.I. Danilovich Drafting the article: I.V. Ganyukov Critical revision of the article: R.S. Tarasov, V.I. Ganyukov Final approval of the version to be published: all authors
- 10 August 2026
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 30 (2) , 67-76
Open AccessValve-in-valve methodologies in transcatheter atrioventricular re-replacement using balloon-expandable prostheses: a series of clinical cases
Introduction: Given the annual increase in the need for repeated heart valve replacement, which is a high-risk surgical procedure due to repeated surgical access against the background of severe adhesions, trauma and comorbidity of patients, the technique of transcatheter heart valve replacement is becoming increasingly relevant and preferable. Objective: To present in detail modern methodologies for transcatheter mitral and tricuspid valve replacement using clinical examples. Methods: The presented patients had dysfunction of a previously openly implanted mitral/tricuspid bioprosthesis according to clinical data and echocardiography. Taking into account the high risk of surgical intervention, resternotomy and comorbid condition, after analyzing multispiral computed tomography within the framework of the cardiac team (cardiologist, endovascular surgeon, cardiovascular surgeon) it was decided to perform endovascular transcatheter repeat replacement using the "valve-in-valve" method. In both cases, puncture vascular access through the common femoral vein was used. Results: Balloon-expandable heart valve prostheses were effectively implanted in patients in the atrioventricular positions, achieving satisfactory hemodynamic parameters. Local anesthesia and transthoracic echocardiography were used for transcatheter tricuspid valve replacement. Mitral valve replacement was performed under total intravenous anesthesia, artificial ventilation, using transesophageal echocardiography, ultra-frequent cardiac pacing, and puncture of the interatrial septum. No complications were detected in the intra- and postoperative periods. The patients were discharged on the seventh day after the intervention. Conclusion: The methodology of transcatheter atrioventricular heart valve replacement is presented using clinical cases as an example, the effectiveness and safety of endovascular mitral and tricuspid valve replacement using balloon-expandable prostheses are shown. Further studies are needed that can provide a comparative assessment of the technologies of transcatheter and surgical atrioventricular heart valve replacement based on the analysis of long-term surgical results. Received 29 April 2025. Revised 28 January 2026. Accepted 3 February 2026. Informed consent The patient's informed consent to use the records for medical purposes is obtained. Funding The study was carried out with financial support from the Ministry of Science and Higher Education of the Russian Federation as part of the research project "Endovascular and extracorporeal technologies for the prevention and treatment of structural heart pathology and critical conditions in cardiac surgery" (No. 0419-2026-0004). Conflict of interest The authors declare no conflict of interest. Contribution of the authors Conception and study design: R.S. Tarasov, V.I. Ganyukov Data collection and analysis: I.V. Ganyukov, A.I. Danilovich Statistical analysis: I.V. Ganyukov, A.I. Danilovich Drafting the article: I.V. Ganyukov Critical revision of the article: R.S. Tarasov, V.I. Ganyukov Final approval of the version to be published: all authors
- 27 May 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (3)
Annual results of percutaneous mitral valve repair using edge-to-edge mitral valve flap coaptation device in patients on the waiting list for heart transplantation
Objective. To analyze the annual results after percutaneous mitral valve repair using edge-to-edge mitral valve coaptation device in patients from the waiting list for heart transplantation. Material and methods. In July 2023, 4 patients underwent percutaneous mitral valve repair with edge-to-edge mitral valve coaptation device for severe mitral regurgitation. Open surgery was refused due to high risk and complicated cardiac diseases (reduced ejection fraction, left ventricular aneurysm, severely decreased left ventricular contractility, pulmonary hypertension, previous cardiac surgeries), and transcatheter intervention was preferred. All patients underwent echocardiography before the intervention, at discharge and one year after correction of mitral regurgitation. Drug therapy, heart failure and adverse cardiovascular events were assessed. Results. All patients were followed-up by a cardiologist and took the prescribed therapy. No significant adverse cardiovascular events were registered throughout the follow-up period. All patients took therapy including diuretics, β-blockers, ACE inhibitors, angiotensin II receptor antagonists, and statins. In long-term follow-up, all patients showed decrease in ejection fraction. In 75% of cases, LV EDV/ESV and pulmonary artery pressure increased compared to in-hospital data. In 3 (75%) patients, mitral insufficiency returned to baseline values after a year. Conclusion. Undoubtedly, percutaneous edge-to-edge mitral valve repair is a fairly promising procedure and provides a chance for favorable outcomes in high-risk patients. This approach can also justify percutaneous intervention as a «bridge» to heart transplantation. However, contradictory data of various studies necessitate further research and accumulation of experience. Therefore, larger samples of patients and analysis of long-term postoperative results will allow us to obtain new knowledge about dynamics of clinical status in patients with CHF and MR, cardiac remodeling and selection criteria for such interventions.
- 27 May 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (3)
Annual results of percutaneous mitral valve repair using edge-to-edge mitral valve flap coaptation device in patients on the waiting list for heart transplantation
Objective. To analyze the annual results after percutaneous mitral valve repair using edge-to-edge mitral valve coaptation device in patients from the waiting list for heart transplantation. Material and methods. In July 2023, 4 patients underwent percutaneous mitral valve repair with edge-to-edge mitral valve coaptation device for severe mitral regurgitation. Open surgery was refused due to high risk and complicated cardiac diseases (reduced ejection fraction, left ventricular aneurysm, severely decreased left ventricular contractility, pulmonary hypertension, previous cardiac surgeries), and transcatheter intervention was preferred. All patients underwent echocardiography before the intervention, at discharge and one year after correction of mitral regurgitation. Drug therapy, heart failure and adverse cardiovascular events were assessed. Results. All patients were followed-up by a cardiologist and took the prescribed therapy. No significant adverse cardiovascular events were registered throughout the follow-up period. All patients took therapy including diuretics, β-blockers, ACE inhibitors, angiotensin II receptor antagonists, and statins. In long-term follow-up, all patients showed decrease in ejection fraction. In 75% of cases, LV EDV/ESV and pulmonary artery pressure increased compared to in-hospital data. In 3 (75%) patients, mitral insufficiency returned to baseline values after a year. Conclusion. Undoubtedly, percutaneous edge-to-edge mitral valve repair is a fairly promising procedure and provides a chance for favorable outcomes in high-risk patients. This approach can also justify percutaneous intervention as a «bridge» to heart transplantation. However, contradictory data of various studies necessitate further research and accumulation of experience. Therefore, larger samples of patients and analysis of long-term postoperative results will allow us to obtain new knowledge about dynamics of clinical status in patients with CHF and MR, cardiac remodeling and selection criteria for such interventions.
- Open Access
- 4 May 2026
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 15 (2) , 149-155
METHODOLOGY OF PACING IN TRANSCATHETER AORTIC VALVE REPLACEMENT USING AN ULTRA-RIGID GUIDEWIRE IN THE LEFT VENTRICLE AND A CORONARY GUIDEWIRE IN THE FEMORAL ARTERY
Highlights Various methods of over-frequency ventricular stimulation in endovascular interventions on heart valves are analyzed. A new method of pacing using an over-stiff guidewire in the left ventricle and a coronary guidewire in the femoral artery is presented in transcatheter aortic valve replacement . Absract The publication presents and substantiates the methodology of pacing in TIAC using an ultra-rigid conductor in the left ventricle and a coronary conductor in the femoral artery. A technique for ultra–frequent stimulation of the ventricles of the heart is described, in particular, the use of a coronary artery in the femoral artery, the approach is illustrated by a clinical example. The proposed method makes it possible to successfully perform transcatheter intervention on the aortic valve: it provides stable, ultra-frequent stimulation of the ventricles at small amplitudes, while it does not require additional manipulations, new accesses, special tools and additional material costs.
- 4 May 2026
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 15 (2) , 149-155
Open AccessMETHODOLOGY OF PACING IN TRANSCATHETER AORTIC VALVE REPLACEMENT USING AN ULTRA-RIGID GUIDEWIRE IN THE LEFT VENTRICLE AND A CORONARY GUIDEWIRE IN THE FEMORAL ARTERY
Highlights Various methods of over-frequency ventricular stimulation in endovascular interventions on heart valves are analyzed. A new method of pacing using an over-stiff guidewire in the left ventricle and a coronary guidewire in the femoral artery is presented in transcatheter aortic valve replacement . Absract The publication presents and substantiates the methodology of pacing in TIAC using an ultra-rigid conductor in the left ventricle and a coronary conductor in the femoral artery. A technique for ultra–frequent stimulation of the ventricles of the heart is described, in particular, the use of a coronary artery in the femoral artery, the approach is illustrated by a clinical example. The proposed method makes it possible to successfully perform transcatheter intervention on the aortic valve: it provides stable, ultra-frequent stimulation of the ventricles at small amplitudes, while it does not require additional manipulations, new accesses, special tools and additional material costs.
- 18 February 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (1)
GP IIb/IIIa platelet receptor inhibitor for acute stent thrombosis with technically impossible percutaneous intervention
Over the past 10—15 years, more than ten blockers of GP IIb/IIIa platelet receptors have been created. Mechanism of their action is blockade of membrane glycoprotein receptors of platelets that leads to suppression of common final pathway of aggregation. GP IIb/IIIa platelet receptor inhibitor eliminated coronary artery thrombosis according to coronary angiography and allowed restoration of coronary blood flow in “no-reflow” phenomenon in 100% of cases. The authors used GP IIb/IIIa inhibitor of platelet receptors for the treatment of acute stent thrombosis with technical impossibility of repeated percutaneous coronary intervention with positive effect.
- 18 February 2026
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (1)
GP IIb/IIIa platelet receptor inhibitor for acute stent thrombosis with technically impossible percutaneous intervention
Over the past 10—15 years, more than ten blockers of GP IIb/IIIa platelet receptors have been created. Mechanism of their action is blockade of membrane glycoprotein receptors of platelets that leads to suppression of common final pathway of aggregation. GP IIb/IIIa platelet receptor inhibitor eliminated coronary artery thrombosis according to coronary angiography and allowed restoration of coronary blood flow in “no-reflow” phenomenon in 100% of cases. The authors used GP IIb/IIIa inhibitor of platelet receptors for the treatment of acute stent thrombosis with technical impossibility of repeated percutaneous coronary intervention with positive effect.
- 30 December 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (6S)
HYBRID REVASCULARIZATION BY MEANS OF CAROTID ENDARTERECTOMY AND PERCUTANEOUS CORONARY INTERVENTION: THIRTEEN-YEAR PATH OF TECHNOLOGY DEVELOPMENT
Highlights Hospital data of patients who received revascularization of the brain and myocardium in the scope of carotid endaratherectomy and percutaneous coronary intervention were analyzed . The development of hybrid revascularization technology in terms of carotid endaratherectomy and percutaneous coronary intervention over the course of thirteen years has been analyzed. Absract Aim. To study the in-hospital outcomes of hybrid intervention in the volume of percutaneous coronary intervention and carotid endarterectomy in the context of thirteen-year dynamics of this technology in patients with severe atherosclerosis of the coronary and carotid bed. Methods. From 2011 to 2023, 301 hybrid interventions (PCI + CEE) were performed in patients with combined significant lesions of the coronary and internal carotid arteries at the Kuzbass Cardiology Center. The choice of treatment strategy for patients was carried out by a multidisciplinary team involving a cardiologist, cardiovascular surgeon, endovascular surgeon and angioneurologist based on current clinical guidelines, local treatment protocols and a personalized approach. The study assessed the clinical, anatomical-angiographic and perioperative status of patients. In-hospital endpoints included death, myocardial infarction, acute cerebrovascular accident/transient ischemic attack, and repeated unplanned myocardial or cerebral revascularization. Results. No fatal outcomes were identified in the analysis of the total sample of patients in the hospital period. The incidence of myocardial infarction was 2.3%, stroke – 2%, unplanned repeat myocardial revascularization – 0.7%, and bleeding – 2.4%. When comparing the two groups (2011–2017 and 2018–2023), no fatal outcomes were recorded in either group. The highest number of MIs was recorded in the early period of hybrid technology implementation (3.08% versus 1.8%). The frequency of repeated unplanned myocardial revascularization in the first group (early period) was slightly higher (1.54% versus 0%). However, in terms of the frequency of stroke, the second group (late period) was in the lead (0% versus 3.5%). In this regard, the final combined (MACE) point in the second group was higher (3.08% versus 5.3%). Conclusion. Thus, hybrid myocardial and cerebral revascularization in the volume of PCI and CEE is a promising and safe method for treating patients with multifocal atherosclerosis, characterized by an extremely low probability of hospital mortality, and satisfactory indicators of the risks of other adverse cardiovascular events (MI and stroke). The implementation of the hybrid treatment strategy eliminates the risks of patient no-show at the second stage of revascularization for subjective and objective reasons, reduces the likelihood of a cardiovascular catastrophe while waiting for the second stage of treatment. Thirteen years of implementation of this technology in a single center demonstrates stable, sustainable and encouraging hospital outcomes and complication risks depending on the initial characteristics of patients.
- 30 December 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (6S)
HYBRID REVASCULARIZATION BY MEANS OF CAROTID ENDARTERECTOMY AND PERCUTANEOUS CORONARY INTERVENTION: THIRTEEN-YEAR PATH OF TECHNOLOGY DEVELOPMENT
Highlights Hospital data of patients who received revascularization of the brain and myocardium in the scope of carotid endaratherectomy and percutaneous coronary intervention were analyzed . The development of hybrid revascularization technology in terms of carotid endaratherectomy and percutaneous coronary intervention over the course of thirteen years has been analyzed. Absract Aim. To study the in-hospital outcomes of hybrid intervention in the volume of percutaneous coronary intervention and carotid endarterectomy in the context of thirteen-year dynamics of this technology in patients with severe atherosclerosis of the coronary and carotid bed. Methods. From 2011 to 2023, 301 hybrid interventions (PCI + CEE) were performed in patients with combined significant lesions of the coronary and internal carotid arteries at the Kuzbass Cardiology Center. The choice of treatment strategy for patients was carried out by a multidisciplinary team involving a cardiologist, cardiovascular surgeon, endovascular surgeon and angioneurologist based on current clinical guidelines, local treatment protocols and a personalized approach. The study assessed the clinical, anatomical-angiographic and perioperative status of patients. In-hospital endpoints included death, myocardial infarction, acute cerebrovascular accident/transient ischemic attack, and repeated unplanned myocardial or cerebral revascularization. Results. No fatal outcomes were identified in the analysis of the total sample of patients in the hospital period. The incidence of myocardial infarction was 2.3%, stroke – 2%, unplanned repeat myocardial revascularization – 0.7%, and bleeding – 2.4%. When comparing the two groups (2011–2017 and 2018–2023), no fatal outcomes were recorded in either group. The highest number of MIs was recorded in the early period of hybrid technology implementation (3.08% versus 1.8%). The frequency of repeated unplanned myocardial revascularization in the first group (early period) was slightly higher (1.54% versus 0%). However, in terms of the frequency of stroke, the second group (late period) was in the lead (0% versus 3.5%). In this regard, the final combined (MACE) point in the second group was higher (3.08% versus 5.3%). Conclusion. Thus, hybrid myocardial and cerebral revascularization in the volume of PCI and CEE is a promising and safe method for treating patients with multifocal atherosclerosis, characterized by an extremely low probability of hospital mortality, and satisfactory indicators of the risks of other adverse cardiovascular events (MI and stroke). The implementation of the hybrid treatment strategy eliminates the risks of patient no-show at the second stage of revascularization for subjective and objective reasons, reduces the likelihood of a cardiovascular catastrophe while waiting for the second stage of treatment. Thirteen years of implementation of this technology in a single center demonstrates stable, sustainable and encouraging hospital outcomes and complication risks depending on the initial characteristics of patients.
- Open Access
- 14 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9S) , 6369
Types of percutaneous coronary interventions in ST-segment elevation myocardial infarction
In ST-segment elevation myocardial infarction (STEMI), various types of percutaneous coronary intervention (PCI) are performed depending on the disease duration, persistent disease symptoms, and prior thrombolytic therapy.The aim of this review is to present all PCI types that can be performed in the treatment of patients with STEMI, substantiate the indications for their use, and the optimal option for endovascular intervention.Basically, three following types of PCI used in patients with STEMI are distinguished: primary PCI (PPCI), late PCI (after 48 hours from the disease onset), and PCI after thrombolytic therapy. Different types of PCI in STEMI have different benefits. Current guidelines substantiate absolute indications for stenting with the highest level of evidence for 12-hour PPCI, rescue PCI, and routine early PCI after thrombolytic therapy. At the same time, the priority role in reperfusion in STEMI is assigned to 12-hour PPCI. That is why this indicator is a target in the European Stent for Life (SFL) initiative — the national/regional indicator of 12-hour PPCI should be 70% or higher of the number of patients hospitalized with STEMI.
- 14 October 2025
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (9S) , 6369
Open AccessTypes of percutaneous coronary interventions in ST-segment elevation myocardial infarction
In ST-segment elevation myocardial infarction (STEMI), various types of percutaneous coronary intervention (PCI) are performed depending on the disease duration, persistent disease symptoms, and prior thrombolytic therapy.The aim of this review is to present all PCI types that can be performed in the treatment of patients with STEMI, substantiate the indications for their use, and the optimal option for endovascular intervention.Basically, three following types of PCI used in patients with STEMI are distinguished: primary PCI (PPCI), late PCI (after 48 hours from the disease onset), and PCI after thrombolytic therapy. Different types of PCI in STEMI have different benefits. Current guidelines substantiate absolute indications for stenting with the highest level of evidence for 12-hour PPCI, rescue PCI, and routine early PCI after thrombolytic therapy. At the same time, the priority role in reperfusion in STEMI is assigned to 12-hour PPCI. That is why this indicator is a target in the European Stent for Life (SFL) initiative — the national/regional indicator of 12-hour PPCI should be 70% or higher of the number of patients hospitalized with STEMI.
- Open Access
- 13 July 2025
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 40 (2) , 168-175
Stenting of critical aortic coarctation in adult patient with low ejection fraction and pulmonary hypertension: a clinical case
Introduction. Coarctation of the aorta (CoAo) occurs in approximately 2–5 per 10,000 births and currently accounts for about 30% of congenital heart defects. When diagnosing CoAo in adults, the cardiac team often deals with decompensated comorbid patients at high surgical risk with reduced cardiac contractility, pulmonary hypertension (PH), and congestive heart failure. In such a situation, the endovascular correction method, consisting of CoAo stenting, may be the only possible treatment method that gives a chance for patient survival. At the same time, the issues of reversibility of the processes of pathological remodeling of the myocardium and PH during the correction of CoAo in adulthood have not been fully studied and are of high scientific and practical interest.Aim: To demonstrate the results of stenting of critical coarctation of the aorta in an adult patient at high surgical risk with low ejection fraction and pulmonary hypertension and to evaluate the degree of reversibility of pathological cardiac remodeling and pulmonary hypertension.Material and Methods. Patient M., 27 years old, consulted a cardiologist on an outpatient basis with complaints of pain in the left half of the chest, an increase in abdominal volume, and attacks of cardiac asthma at night after suffering an acute respiratory illness. Critical coarctation of the aorta in a typical location and bicuspid aortic valve insufficiency were diagnosed. Taking into account the clinical status, a pronounced decrease in cardiac contractility (ejection fraction 32%), high pulmonary hypertension (systolic pressure in the pulmonary artery 90 mmHg), the patient was considered inoperable for open surgery. Therefore, the cardiac team chose treatment tactics in favor of aortic stenting in the coarctation zone.Results. In this case, CoAo stenting became the only possible treatment method for an inoperable young patient. In the postoperative period, regression of complaints of chest pain and cardiac asthma was noted, and normalization of blood pressure was achieved while receiving therapy. Positive changes in the echocardiographic picture consisted of an increase in LVEF from 32 to 66%, a decrease in the average pressure in the pulmonary artery from 58 to 22 mm. rt. art., reducing the end systolic volume of the left ventricle from 147 to 72 ml. When examining the patient after 6 months. after CoAo stenting, a satisfactory clinical effect and normalization of the echocardiographic picture remained in the form of a further increase in LVEF and complete regression of high PH. The minimally invasive nature of the intervention, rapid rehabilitation and low risk of developing infectious and neurological complications made this method even more justified.Conclusions. The results obtained demonstrated that CoAo stenting in an adult patient of very high surgical risk was the only possible safe and effective method of correction, which had a pronounced positive effect on cardiac remodeling and eliminated PH. CoAo stenting can be considered as the first stage of treatment towards surgical correction of concomitant aortic valve disease, allowing the decompensated patient to be stabilized, transferred from a very high to a low surgical risk group.
- 13 July 2025
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 40 (2) , 168-175
Open AccessStenting of critical aortic coarctation in adult patient with low ejection fraction and pulmonary hypertension: a clinical case
Introduction. Coarctation of the aorta (CoAo) occurs in approximately 2–5 per 10,000 births and currently accounts for about 30% of congenital heart defects. When diagnosing CoAo in adults, the cardiac team often deals with decompensated comorbid patients at high surgical risk with reduced cardiac contractility, pulmonary hypertension (PH), and congestive heart failure. In such a situation, the endovascular correction method, consisting of CoAo stenting, may be the only possible treatment method that gives a chance for patient survival. At the same time, the issues of reversibility of the processes of pathological remodeling of the myocardium and PH during the correction of CoAo in adulthood have not been fully studied and are of high scientific and practical interest.Aim: To demonstrate the results of stenting of critical coarctation of the aorta in an adult patient at high surgical risk with low ejection fraction and pulmonary hypertension and to evaluate the degree of reversibility of pathological cardiac remodeling and pulmonary hypertension.Material and Methods. Patient M., 27 years old, consulted a cardiologist on an outpatient basis with complaints of pain in the left half of the chest, an increase in abdominal volume, and attacks of cardiac asthma at night after suffering an acute respiratory illness. Critical coarctation of the aorta in a typical location and bicuspid aortic valve insufficiency were diagnosed. Taking into account the clinical status, a pronounced decrease in cardiac contractility (ejection fraction 32%), high pulmonary hypertension (systolic pressure in the pulmonary artery 90 mmHg), the patient was considered inoperable for open surgery. Therefore, the cardiac team chose treatment tactics in favor of aortic stenting in the coarctation zone.Results. In this case, CoAo stenting became the only possible treatment method for an inoperable young patient. In the postoperative period, regression of complaints of chest pain and cardiac asthma was noted, and normalization of blood pressure was achieved while receiving therapy. Positive changes in the echocardiographic picture consisted of an increase in LVEF from 32 to 66%, a decrease in the average pressure in the pulmonary artery from 58 to 22 mm. rt. art., reducing the end systolic volume of the left ventricle from 147 to 72 ml. When examining the patient after 6 months. after CoAo stenting, a satisfactory clinical effect and normalization of the echocardiographic picture remained in the form of a further increase in LVEF and complete regression of high PH. The minimally invasive nature of the intervention, rapid rehabilitation and low risk of developing infectious and neurological complications made this method even more justified.Conclusions. The results obtained demonstrated that CoAo stenting in an adult patient of very high surgical risk was the only possible safe and effective method of correction, which had a pronounced positive effect on cardiac remodeling and eliminated PH. CoAo stenting can be considered as the first stage of treatment towards surgical correction of concomitant aortic valve disease, allowing the decompensated patient to be stabilized, transferred from a very high to a low surgical risk group.
- 12 February 2025
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 18 (1)
Long-term outcomes after ethanol septal ablation in the treatment of patients with hypertrophic cardiomyopathy
Objective. To analyze the long-term outcomes in patients with hypertrophic cardiomyopathy (HCM) after ethanol septal ablation (ESA). Material and methods. There were 25 ESA procedures in patients with HCM and left ventricular outflow tract (LVOT) obstruction between January 2018 and September 2022. Mean age of patients was 61 [43; 80] years, women prevailed (60%). All patients had HCM with LVOT obstruction and peak pressure gradient ≥50 mm Hg. Before ESA, patients underwent balloon occlusion of septal branch, and intervention was performed only when peak pressure gradient decreased by 50% or more. Results. One patient died from tumor of the frontal and temporal lobe. Another patient experienced non-fatal stroke. There were no repeated interventions on LVOT, myocardial infarctions or pacemaker implantations. Survey revealed that 5 (24%) patients had recurrence of angina pectoris, 11 (52%) — shortness of breath, 8 (38%) — fatigue despite low peak pressure gradient (<35 mm Hg) after ESA. Conclusion. Taking into account the long-term results in this study (22 [7; 40] months), we can emphasize high effectiveness and safety of ESA in these patients. Together with literature data, it is a serious argument in favor of this technology in various hospitals engaged in high-tech medical care for patients with HCM.
- 12 February 2025
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 18 (1)
Long-term outcomes after ethanol septal ablation in the treatment of patients with hypertrophic cardiomyopathy
Objective. To analyze the long-term outcomes in patients with hypertrophic cardiomyopathy (HCM) after ethanol septal ablation (ESA). Material and methods. There were 25 ESA procedures in patients with HCM and left ventricular outflow tract (LVOT) obstruction between January 2018 and September 2022. Mean age of patients was 61 [43; 80] years, women prevailed (60%). All patients had HCM with LVOT obstruction and peak pressure gradient ≥50 mm Hg. Before ESA, patients underwent balloon occlusion of septal branch, and intervention was performed only when peak pressure gradient decreased by 50% or more. Results. One patient died from tumor of the frontal and temporal lobe. Another patient experienced non-fatal stroke. There were no repeated interventions on LVOT, myocardial infarctions or pacemaker implantations. Survey revealed that 5 (24%) patients had recurrence of angina pectoris, 11 (52%) — shortness of breath, 8 (38%) — fatigue despite low peak pressure gradient (<35 mm Hg) after ESA. Conclusion. Taking into account the long-term results in this study (22 [7; 40] months), we can emphasize high effectiveness and safety of ESA in these patients. Together with literature data, it is a serious argument in favor of this technology in various hospitals engaged in high-tech medical care for patients with HCM.
- Open Access
- 28 December 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (4S) , 65-72
IN-HOSPITAL OUTCOMES OF ALCOHOL SEPTAL ABLATION IN THE TREATMENT OF PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS: RESULTS OF A SINGLE CENTER STUDY
Highlights The review is devoted to the analysis of baseline and in-hospital outcomes of patients with hypertrophic cardiomyopathy after alcohol septal ablation. The results showed that efficacy and safety of alcohol septal ablation in the treatment of patients with hypertrophic cardiomyopathy is comparable to surgical myectomy of the left ventricular outflow tract. Aim. To analyze cases of patients undergoing alcohol septal ablation (ASA) at the Research Institute, assessing patients' baseline status, perioperative data and in-hospital outcomes, and to prove that efficacy and safety of ASA in the treatment of patients with hypertrophic cardiomyopathy (HCM) is comparable to surgical myectomy of the left ventricular outflow tract (LVOT) taking into account the available literature data.Materials and Methods. The study included 25 patients with HCM and LVOT obstruction who underwent ASA at the Research Institute for Complex Issues of Cardiovascular Diseases between 2018 and September 2022. The feasibility of the procedure was based on echocardiographic (LVOT obstruction with peak gradient ≥ 50 mm Hg) and angiographic data (absence of coronary bed lesions, and presence of septal branches with diameter of at least 2 mm). The intervention was performed only in case of a “positive” balloon test, i.e. peak gradient decrease by 30% or more compared to baseline during balloon inflation in the target septal branch.Results. We considered the decrease of LVOT peak gradient by more than 50% compared to baseline to be a success criterion of the procedure. In in-hospital setting there were no endpoints (death, stroke, blockage of left anterior descending artery, permanent pacemaker implantation), and temporary cardiac pacing was required only in 2 cases (8%) due to transient AV blockade. The echocardiography showed that the peak LVOT pressure gradient was 35 [10; 87] mmHg on the 1st day, and 20 [8; 75] mmHg on the 5th day. Conclusion. The findings and the experience of other clinics proved that ASA can be used in the treatment of patients with HCM and is comparable to surgical myectomy in terms of efficacy. However, patient selection for ASA should be thorough and include clinical and demographic indicators, and echocardiography and angiography data.
- 28 December 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (4S) , 65-72
Open AccessIN-HOSPITAL OUTCOMES OF ALCOHOL SEPTAL ABLATION IN THE TREATMENT OF PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS: RESULTS OF A SINGLE CENTER STUDY
Highlights The review is devoted to the analysis of baseline and in-hospital outcomes of patients with hypertrophic cardiomyopathy after alcohol septal ablation. The results showed that efficacy and safety of alcohol septal ablation in the treatment of patients with hypertrophic cardiomyopathy is comparable to surgical myectomy of the left ventricular outflow tract. Aim. To analyze cases of patients undergoing alcohol septal ablation (ASA) at the Research Institute, assessing patients' baseline status, perioperative data and in-hospital outcomes, and to prove that efficacy and safety of ASA in the treatment of patients with hypertrophic cardiomyopathy (HCM) is comparable to surgical myectomy of the left ventricular outflow tract (LVOT) taking into account the available literature data.Materials and Methods. The study included 25 patients with HCM and LVOT obstruction who underwent ASA at the Research Institute for Complex Issues of Cardiovascular Diseases between 2018 and September 2022. The feasibility of the procedure was based on echocardiographic (LVOT obstruction with peak gradient ≥ 50 mm Hg) and angiographic data (absence of coronary bed lesions, and presence of septal branches with diameter of at least 2 mm). The intervention was performed only in case of a “positive” balloon test, i.e. peak gradient decrease by 30% or more compared to baseline during balloon inflation in the target septal branch.Results. We considered the decrease of LVOT peak gradient by more than 50% compared to baseline to be a success criterion of the procedure. In in-hospital setting there were no endpoints (death, stroke, blockage of left anterior descending artery, permanent pacemaker implantation), and temporary cardiac pacing was required only in 2 cases (8%) due to transient AV blockade. The echocardiography showed that the peak LVOT pressure gradient was 35 [10; 87] mmHg on the 1st day, and 20 [8; 75] mmHg on the 5th day. Conclusion. The findings and the experience of other clinics proved that ASA can be used in the treatment of patients with HCM and is comparable to surgical myectomy in terms of efficacy. However, patient selection for ASA should be thorough and include clinical and demographic indicators, and echocardiography and angiography data.